Brazil

Population 2017 209 million

- Estimates of TB burden*, 2017
  - Number (thousands) Rate per 100 000 population
    - Mortality (excludes HIV+TB) 5.1 (4.8–5.3) 2.4 (2.3–2.5)
    - Mortality (HIV+TB only) 1.9 (1.4–2.5) 0.91 (0.67–1.2)
    - Incidence (includes HIV+TB) 91 (78–105) 44 (37–50)
    - Incidence (HIV+TB only) 11 (9.3–13) 5.3 (4.5–6.3)
    - Incidence (MDR/RR-TB)** 2.4 (1.8–3.1) 1.2 (0.88–1.5)

- Estimated TB incidence by age and sex (thousands)*, 2017
  - 0-14 years
    - Females 5.2 (5–5.4) 24 (22–26) 29 (27–32)
    - Males 5.7 (5.5–5.9) 56 (50–63) 62 (54–70)
  - > 14 years
    - Total 11 (10–11) 80 (69–92) 91 (78–105)

- TB case notifications, 2017
  - Total cases notified 86 858
  - Total new and relapse 79 222
    - % tested with rapid diagnostics at time of diagnosis 26%
    - % with known HIV status 78%
    - % pulmonary 87%
    - % bacteriologically confirmed among pulmonary 72%

- Universal health coverage and social protection
  - TB treatment coverage (notified/estimated incidence), 2017 87% (75–100)
  - TB patients facing catastrophic total costs 0.08 (0.06–0.09)
  - TB/HIV care in new and relapse TB patients, 2017 (Number (%) of patients with known HIV-status who are HIV-positive)
    - on antiretroviral therapy 7 831 13%

- Drug-resistant TB care, 2017
  - New cases 2 000
  - Previously treated cases 1 600–2 400
  - Total number*** MDR/RR-TB: 1 110, XDR-TB: 16
  - Estimated % of TB cases with MDR/RR-TB 1.5% (1.1–2) 8% (6–10)
  - % notified tested for rifampicin resistance 30% 39% 27 716
  - MDR/RR-TB cases tested for resistance to second-line drugs 173
  - Laboratory-confirmed cases
    - MDR/RR-TB: 1 110, XDR-TB: 16
    - Patients started on treatment ****
      - MDR/RR-TB: 964, XDR-TB: 16

- Treatment success rate and cohort size
  - New and relapse cases registered in 2016 72% 75 223
  - Previously treated cases, excluding relapse, registered in 2016 39% 7 251
  - HIV-positive TB cases registered in 2016 53% 7 366
  - MDR/RR-TB cases started on second-line treatment in 2015 60% 954
  - XDR-TB cases started on second-line treatment in 2015 11% 27

- TB preventive treatment, 2017
  - % of HIV-positive people (newly enrolled in care) on preventive treatment
  - % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

- TB financing, 2018
  - National TB budget (US$ millions) 57
    - Funding source: 85% domestic, 0% international, 15% unfunded

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Data: www.who.int/tb/data